OBJECTIVE: To evaluate the evidence of the supplements vitamin C and vitamin E for treatment and prevention of cancer. METHODS: Systematic review of trials and meta-analysis. DATA SOURCES AND MAIN RESULTS: Thirty-eight studies showed scant evidence that vitamin C or vitamin E beneficially affects survival. In the ATBC Cancer Prevention Study Group, no statistically significant effect of treatment was seen for any cancer individually, and our pooled relative risk (regardless of tumor type) for alpha-tocopherol alone was 0.91 (95% confidence interval [CI]: 0.74, 1.12). All cause mortality was not significant. In the Linxian General Population Trial, the relative risks for cancer death for vitamin C (combined with molybdenum) was 1.06 (95% CI: 0.92, 1.21) and for vitamin E (combined with beta-carotene and selenium) was 0.87 (95% CI: 0.76, 1.00). We identified only 3 studies that reported statistically significant beneficial results: vitamin C (in combination with BCG) was found to be beneficial in a single trial of bladder cancer and vitamin E (in combination with omega-3 fatty acid) increased survival in patients with advanced cancer. In the ATBC trial, in analyses of 6 individual cancers, the prevention of prostate cancer in subjects treated with alpha-tocopherol was statistically significant (RR=0.64, 95% CI: 0.44, 0.94). CONCLUSIONS: The systematic review of the literature does not support the hypothesis that the use of supplements of vitamin C or vitamin E in the doses tested helps prevent and/or treat cancer in the populations tested. There were isolated findings of benefit, which require confirmation.
OBJECTIVE: To evaluate the evidence of the supplements vitamin C and vitamin E for treatment and prevention of cancer. METHODS: Systematic review of trials and meta-analysis. DATA SOURCES AND MAIN RESULTS: Thirty-eight studies showed scant evidence that vitamin C or vitamin E beneficially affects survival. In the ATBCCancer Prevention Study Group, no statistically significant effect of treatment was seen for any cancer individually, and our pooled relative risk (regardless of tumor type) for alpha-tocopherol alone was 0.91 (95% confidence interval [CI]: 0.74, 1.12). All cause mortality was not significant. In the Linxian General Population Trial, the relative risks for cancer death for vitamin C (combined with molybdenum) was 1.06 (95% CI: 0.92, 1.21) and for vitamin E (combined with beta-carotene and selenium) was 0.87 (95% CI: 0.76, 1.00). We identified only 3 studies that reported statistically significant beneficial results: vitamin C (in combination with BCG) was found to be beneficial in a single trial of bladder cancer and vitamin E (in combination with omega-3 fatty acid) increased survival in patients with advanced cancer. In the ATBC trial, in analyses of 6 individual cancers, the prevention of prostate cancer in subjects treated with alpha-tocopherol was statistically significant (RR=0.64, 95% CI: 0.44, 0.94). CONCLUSIONS: The systematic review of the literature does not support the hypothesis that the use of supplements of vitamin C or vitamin E in the doses tested helps prevent and/or treat cancer in the populations tested. There were isolated findings of benefit, which require confirmation.
Authors: H J Bussey; J J DeCosse; E E Deschner; A A Eyers; M L Lesser; B C Morson; S M Ritchie; J P Thomson; J Wadsworth Journal: Cancer Date: 1982-10-01 Impact factor: 6.860
Authors: E T Creagan; C G Moertel; J R O'Fallon; A J Schutt; M J O'Connell; J Rubin; S Frytak Journal: N Engl J Med Date: 1979-09-27 Impact factor: 91.245
Authors: E R Greenberg; J A Baron; T D Tosteson; D H Freeman; G J Beck; J H Bond; T A Colacchio; J A Coller; H D Frankl; R W Haile Journal: N Engl J Med Date: 1994-07-21 Impact factor: 91.245
Authors: Mei Chung; Ethan M Balk; Stanley Ip; Gowri Raman; Winifred W Yu; Thomas A Trikalinos; Alice H Lichtenstein; Elizabeth A Yetley; Joseph Lau Journal: Am J Clin Nutr Date: 2009-02-25 Impact factor: 7.045
Authors: Qian Li; Shu-Chun Chuang; Jose Eluf-Neto; Ana Menezes; Elena Matos; Sergio Koifman; Victor Wünsch-Filho; Leticia Fernandez; Alexander W Daudt; Maria Paula Curado; Deborah M Winn; Silvia Franceschi; Rolando Herrero; Xavier Castellsague; Hal Morgenstern; Zuo-Feng Zhang; Philip Lazarus; Joshua Muscat; Michael McClean; Karl T Kelsey; Richard B Hayes; Mark P Purdue; Stephen M Schwartz; Chu Chen; Simone Benhamou; Andrew F Olshan; Guopei Yu; Stimson Schantz; Gilles Ferro; Paul Brennan; Paolo Boffetta; Mia Hashibe Journal: Int J Cancer Date: 2012-01-27 Impact factor: 7.396
Authors: Jennifer Lin; Nancy R Cook; Christine Albert; Elaine Zaharris; J Michael Gaziano; Martin Van Denburgh; Julie E Buring; JoAnn E Manson Journal: J Natl Cancer Inst Date: 2008-12-30 Impact factor: 13.506